How US Drug Pricing Reforms Are Reshaping Innovation

Directors Digest

How US Drug Pricing Reforms Are Reshaping Innovation

João L. Carapinha, Ph.D.

US drug pricing reforms have fundamentally altered the economics of biopharmaceutical innovation. Multiple administrations have attempted to curb escalating healthcare costs while maintaining the United States as the primary launch market for breakthrough therapies. These changes carry profound consequences for market access, health economics, and global innovation pipelines.

Recent policies, notably the Inflation Reduction Act and the 2025 Most-Favored-Nation executive order, signal a clear shift. Industry leaders now accept that structural adjustments have become unavoidable. This article examines the implications of these reforms and offers practical insights for senior decision-makers.

Historical Context and Current Trends

For generations, the US healthcare system has funded a disproportionate share of global research and development. American patients and payers have subsidised innovation that benefits markets worldwide. Today, cell and gene therapies can cost several million dollars per patient. The key issue is how society will continue to fund access to such advanced treatments.

Stakeholders across the spectrum recognise that simply continuing previous practices no longer works. New therapies must demonstrably improve outcomes, reduce hospitalisations, and enhance quality of life if the system is to remain viable.

Core Policy Changes

The Inflation Reduction Act empowered the Centers for Medicare and Medicaid Services to negotiate prices for high-expenditure drugs. It also introduced inflation rebates for price increases above the inflation rate. The current administration has expanded this approach through executive action.

The Most Favored Nation policy, introduced via executive order in May 2025, ties US prices to the lowest rate paid in comparable OECD countries. Companies face 100 percent tariffs on patented products unless they sign agreements covering both domestic manufacturing commitments and MFN pricing for Medicaid and the TrumpRx platform. As of February 2026, 14 of the 17 largest global pharmaceutical companies have accepted these terms in exchange for three-year tariff relief.

Industry Adaptation Strategies

Biopharmaceutical companies have responded with notable portfolio adjustments. Many organisations now prioritise orphan drugs, oncology, and rare disease programmes that typically enjoy longer exclusivity and face reduced exposure to Medicare price negotiation. Companies have also shifted investment toward biologics and advanced therapy modalities. Small-molecule programmes now carry greater risk due to faster negotiation timelines under the IRA. Organisational agility has also become essential, via structures that support rapid decision-making and flexibility in response to regulatory and market changes.

Critical Gaps in Current Reforms

Despite these measures, important structural issues remain unaddressed. Pharmacy Benefit Managers continue to capture substantial value within the system. Industry executives note that roughly 50 percent of drug value flows to intermediaries rather than to innovators or patients. Patients will only see savings once the rebate system directs savings directly to patients at the point of sale and PBMs transition to flat-fee compensation models.

The generics sector also faces unintended pressure. Although generics account for 90 percent of prescriptions filled in the US, they represent only 8 to 10 percent of total drug expenditure. American generic prices stand at approximately 60 percent of European levels. This situation has contributed to between 300 and 350 ongoing product shortages, a problem far less prevalent in Canada or Europe.

Global and Economic Implications

US drug pricing policy increasingly influences international launch strategies. Some companies now consider delaying launches in lower-priced markets to protect US pricing levels. Concerns have also emerged about potential reductions in research and development investment, particularly for programmes targeting smaller patient populations.

Europe currently provides access to only about half the innovative medicines available in the United States, while Asia offers roughly one third. Any contraction in US innovation incentives would therefore affect patients globally.

Recommendations for Decision-Makers

Implement comprehensive Pharmacy Benefit Manager reform to ensure negotiated prices deliver genuine patient benefit.
Apply differentiated pricing policies that protect the economic sustainability of the generics market and prevent drug shortages.
Design incentive structures that continue to reward breakthrough innovation while addressing system inefficiencies.
Invest in robust real-world evidence generation to demonstrate value and support outcomes-based agreements.
Develop greater organisational agility to respond effectively to evolving policy and market conditions.

US drug pricing reforms have introduced new rules that all stakeholders must master. While the objective of improving affordability remains valid, success depends on addressing the full complexity of the system. Policymakers, industry leaders, and payers share responsibility for creating frameworks that sustain innovation while delivering tangible benefits to patients.

The coming years will test whether these changes produce sustainable improvements in both cost control and therapeutic progress. Close monitoring and adaptive strategies will prove essential for all participants in the healthcare ecosystem.